HI-CLEARANCE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 138 TWD | 0.00% |
|
-0.36% | +1.85% |
| 15/05 | Hi-Clearance Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 01/03 | Hi-Clearance Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 4.69B 145M 12.11B | Sales 2023 | 3.9B 120M 10.06B | Capitalization | 6.03B 186M 15.58B |
|---|---|---|---|---|---|
| Net income 2022 | 366M 11.31M 945M | Net income 2023 | 348M 10.76M 899M | EV / Sales 2022 | 1.38 x |
| Net Debt 2022 | 660M 20.39M 1.7B | Net Debt 2023 | 192M 5.92M 495M | EV / Sales 2023 | 1.6 x |
| P/E ratio 2022 |
15.9
x | P/E ratio 2023 |
17
x | Employees | - |
| Yield 2022 |
4.86% | Yield 2023 |
5.17% | Free-Float | 60.27% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.36% | ||
| Current month | -2.82% | ||
| 1 month | -3.83% | ||
| 3 months | -1.08% | ||
| 6 months | +2.22% | ||
| Current year | +1.85% |
1 week
136.50
139.50
1 month
136.50147.00
Current year
132.50147.00
1 year
131.00147.50
3 years
131.00191.00
5 years
95.00191.00
10 years
78.10191.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kuo Shih Chen
CEO | Chief Executive Officer | - | 30/95/30 |
Ying Fen Li
DFI | Director of Finance/CFO | - | 12/02/12 |
Yun Ming Wu
BRD | Director/Board Member | - | 29/10/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chung Liang Li
CHM | Chairman | 71 | - |
Ping Hsun Chiang
BRD | Director/Board Member | - | 30/95/30 |
Ying Fen Li
DFI | Director of Finance/CFO | - | 12/02/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 138 | 0.00% | 22,854 |
| 20/24/20 | 138 | +0.73% | 21,187 |
| 19/24/19 | 137 | -0.72% | 124,965 |
| 18/24/18 | 138 | 0.00% | 29,684 |
| 17/24/17 | 138 | -0.36% | 87,012 |
End-of-day quote Taipei Exchange, June 21, 2024
More quotes
Hi-Clearance Inc. is a Taiwan-based company principally engaged in the sales of medical equipment, biochemical reagents and western medicines. The Company's main products include artificial kidneys, kidney dialysis machines, blood circuit tubes, nutritional products for chronic kidney diseases, erythropoietin, cardiology products, medicinal liquid, dental and stomatology products, home health products and others. The Company also provides medical equipment maintenance services. The Company distributes its products mainly in domestic market.
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.85% | 190M | |
| -3.95% | 184B | |
| -0.90% | 109B | |
| -2.27% | 68.87B | |
| +15.24% | 46.61B | |
| -6.00% | 46.39B | |
| +5.36% | 40.74B | |
| +20.65% | 31.26B | |
| -5.50% | 24.24B | |
| +11.60% | 24B |
- Stock Market
- Equities
- 1788 Stock
